Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
John W. Ostrominski(Brigham and Women's Hospital), Muthiah Vaduganathan(Harvard University), Milton Packer(Dana-Farber/Harvard Cancer Center), Brian Claggett(National Heart Lung and Blood Institute), Pardeep S. Jhund(Copenhagen University Hospital), John J.V. McMurray(Western Infirmary), Marc A. Pfeffer(Brigham and Women's Hospital), Jawad H. Butt(Copenhagen University Hospital), Faı̈ez Zannad(Inserm), Mats Christian Højbjerg Lassen(University of Copenhagen), Michael R. Zile(Wm. Jennings Bryan Dorn VA Medical Center), Carolyn S.P. Lam, Akshay S. Desai(Brigham and Women's Hospital), Bertram Pitt(University of Michigan–Ann Arbor), Scott Solomon(Brigham and Women's Hospital), Inder S. Anand(University of Minnesota)
Cited by 18
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k